...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of headache and pain >Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
【24h】

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination

机译：Erenumab和Galcanezumab在慢性偏头痛预防：治疗后的效果终止

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Monoclonal antibodies (mAbs) targeting the CGRP pathway are safe and efficacious therapies for the prevention of migraine. In this study we assessed the effects of discontinuation of preventive erenumab and galcanezumab treatment in patients with chronic migraine. This retrospective pooled analysis included completers of the open-label extension study phase for the preventive treatment of chronic migraine with galcanezumab (NCT02614261; 9?months) and erenumab (NCT02174861; 12?months) in a single headache center. We compare migraine data until week 12 after open-label treatment completion, when patients did not have any pharmacological preventive medication, to study baseline values of the double-blind trial period, and to the last 4?weeks of the open-label extension. The assessment included changes in monthly migraine days, headache hours, days with severe headache and acute headache medication use. Data from 16 patients after galcanezumab (n?=?9) and erenumab (n?=?7) open-label treatment completion were analyzed. The mean number of monthly migraine days was 18.38?±?3.74 at baseline, and 12.19?±?4.53 in the last 4?weeks of the open-label extension (p??0.001). Monthly migraine days remained significantly reduced compared to baseline during the entire 12-week observation period after open-label termination (p?=?0.002), with a reduction of 5.38?±?4.92 in weeks 1-4 (p?=?0.001), 4.75?±?4.15 in weeks 5-8 (p?=?0.001), and 3.93?±?5.45 in weeks 9-12 (p?=?0.014). There was no significant difference in monthly migraine days between the 12?weeks after open-label termination and the last 4?weeks of the open-label phase (p?=?0.228). All other analyses revealed numerical improvement through week 12 in comparison to baseline. In this small, self-selected cohort, the results indicate a therapeutic effect of monoclonal antibodies targeting the CRGP pathway in chronic migraine prevention after treatment termination up to 12?weeks.
机译：靶向CGRP途径的单克隆抗体（MAB）是防止偏头痛的安全性和有效的疗法。在这项研究中，我们评估了在慢性偏头痛患者中停止预防erenumab和Galcanezumab治疗的影响。该回顾性汇总分析包括开放标签扩展研究阶段的完全转移，用于预防慢性偏头痛与Galcanezumab（NCT02614261; 9？月）和Erenumab（NCT02174861; 12？月）在一个头痛中心中的预防性处理。我们将偏头痛数据与第12周进行比较，当患者没有任何药理学预防药物时，研究双盲试验期的基线值，并在最后4个月的开放标签延伸。评估包括每月偏头发日，头痛时间，患有严重头痛和急性头痛药物的日子的变化。分析了16名患者的数据（n？=α9）和Erenumab（n？=Δ7）开放标签治疗完成。每月偏头痛日的平均数为18.38？±3.74，在最近4个？开放标签延伸的最后4个星期（p？<0.001）中，12.19？4.53。与开放标签终止后的整个12周观察期（P？= 0.002）后，与基线相比，每月偏头痛的日子保持显着减少（p？= 0.002），减少5.38？±4.92（p？= 0.001 ），4.75？±4.15周数5-8（p？= 0.001）和3.93？±5.45周内9-12（p？= 0.014）。在开放标签终止后12个星期与开放标签阶段的最后4个星期（P？= 0.228），每月偏头发日内没有显着差异。与基线相比，所有其他分析都通过第12周揭示了数值改进。在这种小型，自选择的队列中，结果表明单克隆抗体靶向CRGP途径在治疗终止后慢性偏头痛预防后的CRGP途径高达12？周。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号